📄 What This Document Is 📜

This is a Proxy Statement (DEF 14A), which is essentially a mandatory informational packet sent to stockholders before a major annual meeting. It isn't an earnings report, but rather a formal guide detailing exactly what decisions the company wants you to vote on.

👉 Why it matters: This document sets the rules for the 2026 Annual Meeting, telling shareholders who the board members are, how management was paid, and what corporate policies are in place.

• Filing Type: Definitive Proxy Statement.
• Purpose: To solicit shareholder votes for the 2026 Annual Meeting.
• Meeting Details: The meeting will be held virtually via live webcast on June 3, 2026, at 10:00 a.m. Pacific Time.
• Voting Instructions: Shareholders are urged to vote and submit their proxy promptly via the Internet, phone, or mail, even if they plan to attend the virtual meeting.

🏢 What Denali Therapeutics Does 🧬

While this proxy statement focuses on governance, it reveals that Denali is a major player in the life sciences sector, focusing on complex neurological diseases.

👉 In simple terms: Denali Therapeutics develops treatments for severe and rare diseases, particularly in the area of neurodegenerative disorders.

• Core Focus: The company shows a deep commitment to therapeutic areas such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), frontotemporal dementia-granulin (FTD-GRN), lysosomal storage diseases (like mucopolysaccharidosis II), and Parkinson's disease (PD).
• Industry Scale: The board members and executives listed have extensive backgrounds across major biotech and pharmaceutical companies (e.g., Genentech, Roche, Vertex Pharmaceuticals), confirming its place in a highly technical, capital-intensive industry.

🗓️ Annual Meeting Details & Timeline 📅

The filing is precise about the logistics of the meeting and when stockholders need to act.

👉 Key Dates: Shareholders must ensure their shares are represented and voted regardless of whether or not they attend the meeting.

• Annual Meeting Date: June 3, 2026, at 10:00 a.m. Pacific Time (Virtual).
• Record Date: The critical date for voting is April 9, 2026. Only stockholders of record at the close of business on this date are entitled to vote.
• Proxy Notice: A Notice of Internet Availability of Proxy Materials is expected to be mailed on or about April 21, 2026.
• Access: Materials can be accessed online at www.virtualshareholdermeeting.com/DNLI2026 and www.proxyvote.com.

🗳️ Proposals Requiring a Vote 📢

The meeting has three primary proposals, which are the votes shareholders are asked to cast.

👉 High-level summary: You are voting on selecting the board's future leadership, confirming the company's accountants, and approving how executives were compensated.

• Proposal No. 1: Election of Directors: Electing three Class III directors, which will serve until the 2029 annual meeting.
• Proposal No. 2: Ratification of Auditors: Approving Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Proposal No. 3: Executive Compensation: Voting (on an advisory basis) on the compensation packages for top executives.

🧑‍⚖️ Corporate Governance & Board Oversight 🛡️

The company takes governance seriously, detailing how its board is structured and how it monitors risk across all facets of the business.

👉 Structure Detail: The board is divided into three classes with staggered three-year terms. This staggered system can make it harder for activist investors to gain immediate control of the board.

• Board Independence: The board affirmed that 8 of the 9 current directors are "independent," meaning their personal relationships with the company do not compromise their judgment.
• Committee Mandate: The board delegates specific risk oversight duties to three standing committees:
  • Audit Committee: Oversights financial reporting, internal controls, and selecting the external accounting firm.
  • Compensation Committee: Oversees executive pay policies and programs.
  • Corporate Governance & Nominating Committee: Reviews governance guidelines and recommends potential board candidates.

🧑‍💼 Board Leadership and Directors 🌐

This section introduces the people running the company—both the current leaders and the nominees for the next class of directors.

👉 Leadership Dynamic: The board has intentionally separated the roles of the Chairperson (Julian C. Baker) and the Chief Executive Officer (Ryan J. Watts, Ph.D.). This separation is intended to enhance objective oversight.

• Class III Nominees: The nominees recommended for Class III directors are Jennifer Cook, David Schenkein, M.D., and Ryan J. Watts, Ph.D. If elected, they serve until the 2029 annual meeting.
• Notable Experience: The biographies highlight decades of experience across the pharmaceutical industry, including roles at major companies like Genentech and Roche.
• Committees: The table shows specific committee memberships, including Peter Klein (Chair of the Audit Committee) and Julian C. Baker (Chairperson of the Compensation Committee).

🤝 The Compensation Review 💸

The Compensation Discussion and Analysis (CD&A) section confirms that executive pay is closely monitored by the Compensation Committee.

👉 Why it matters: The committee confirms that the overall compensation policies are designed to attract and motivate top talent, but they also conduct rigorous risk checks.

• Risk Assessment: The Compensation Committee explicitly reviewed the risk associated with the company’s compensation plans and determined that these risks are not likely to cause a material adverse effect on the Company’s business.
• Compensation Components: Denali's total compensation package consists of cash-based salaries and bonuses, as well as long-term equity incentive grants.

✅ Corporate Governance Policies and Ethics 📜

Denali has established formal guidelines to guide behavior and maintain integrity among its leaders.

👉 Commitment to Integrity: The company mandates that all non-employee directors must maintain a minimum ownership stake of common stock (or qualifying equity) equal to at least three times their base annual cash retainer.

• Code of Conduct: The board has adopted a Code of Business Conduct and Ethics, which applies to all employees, officers, and directors.
• Oversight Function: The board maintains that its key function is to provide "informed oversight" of risk management, dividing these responsibilities among the board as a whole and its standing committees.

🌎 Corporate Responsibility & Operations ♻️

The company provided detailed reports on its impact and practices in areas beyond medicine, focusing on ESG (Environmental, Social, Governance) issues.

👉 Sustainability Efforts: Denali is proactive about minimizing its environmental footprint. They use a "Green Alternative program" that provides researchers with low-impact chemical alternatives for common solvents, and they segregate multiple waste streams (plastics, food waste, glass) for recycling.

• Workplace Safety: They emphasize that since commencing operations in 2015, they have had zero reportable regulatory safety incidents.
• Cybersecurity: The board oversees cybersecurity risk, with the Audit Committee receiving quarterly briefings from the Vice President of Information Technology regarding potential incidents and risk management.
• Community Focus: The company supports organizations dedicated to major neurodegenerative disorders, including ALS, Alzheimer's disease, and Parkinson's disease.

📣 Key Rules for Stockholders 💌

These are the procedural rules that govern voting and communication at the Annual Meeting.

👉 Takeaway: The company is highly formalized regarding shareholder communication, offering detailed methods for voting by Internet, phone, or mail.

• Voting Rights: Stockholders must provide specific voting instructions if they are "beneficial owners" (shares held through a broker), or else the broker may not be able to vote on non-routine proposals (like electing directors).
• Stockholder Proposals: If a shareholder wants to propose business for the 2027 Annual Meeting, written proposals must be received by the Secretary no later than December 22, 2026.
• Contact Information: For questions, shareholders should contact the Secretary at Denali Therapeutics Inc., 161 Oyster Point Blvd. South San Francisco, California 94080, or call (650) 866-8547.

🧠 The Analogy 🏦

Voting on a company's proxy materials is like being a homeowner at a mandatory Homeowners Association (HOA) meeting. You don't run the house day-to-day, but you must vote on the major issues: Should we replace the roofing material (Directors)? Are we trusting the accountant to manage the books (Auditors)? And how much money should we give the managing board (Compensation)? If you don't vote, your votes don't count, and the board makes decisions for you.

🧩 Final Takeaway ✨

This proxy statement confirms Denali is a mature, highly governed biotech firm focused on neurodegenerative diseases. The core message is that shareholders must vote on leadership elections and key policies to ensure the company's strategic direction and financial oversight remain intact.